Post-earnings recap
Reported
Mon, Aug 8, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. The stock's minimal reaction suggests that investors may have anticipated a challenging quarter.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.40 | N/A | -7.38% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of ongoing research and development. They highlighted the need to navigate current market conditions.
Management did not provide specific guidance for future performance.
The company is focused on advancing its pipeline despite current challenges.